4-(2-methoxy-ethoxy)-3-oxo-butyric acid ethyl ester | 130611-26-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: 4-(2-methoxy-ethoxy)-3-oxo-butyric acid ethyl ester
• 英文别名: ethyl 4-(2-methoxyethoxy)-3-oxobutanoate；ethyl 4-(2-methoxyethoxy)acetoacetate；3-oxo-4-methoxyethoxy-butanoic acid ethyl ester
• CAS: 130611-26-6
• 化学式: C₉H₁₆O₅
• 分子量: 204.223
• InChiKey: SYFJNNYHOIAJFL-UHFFFAOYSA-N

物化性质

• 沸点：
  281.5±20.0 °C(Predicted)
• 密度：
  1.072±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(2-methoxy-ethoxy)-3-oxo-butyric acid ethyl ester 在 镍 氢气 、 溴甲酚绿 、 sodium cyanoborohydride 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙醇 、 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ETA receptor selectivity

  摘要：

  Endothelins, ET-1, ET-2, and ET-3 are potent vasoconstricting and mitogenic 21-amino acid bicyclic peptides, which exert their effects upon binding to the ETA and ETB receptors. The ETA receptor mediates vasoconstriction and smooth muscle cell proliferation, and the ETB receptor mediates different effects in different tissues, including nitric oxide release from endothelial cells, and vasoconstriction in certain vascular cell types. Selective antagonists of endothelin receptor subtypes may prove useful in determining the role of endothelin in various tissue types and disease states, and hence as therapeutic agents for such diseases. The pyrrolidine carboxylic acid A-127722 has been disclosed as a potent and ETA-selective antagonist, and is currently undergoing clinical trials. In our efforts to find antagonists with altered selectivity (ETA-selective, ETB-selective, or nonselective), we investigated the SAR of the 2-substituent on the pyrrolidine. Compounds with alkyl groups at the 2-position possessed ETA selectivity improved over A-127722 (1400-fold selective), with the best of these compounds showing nearly 19,000-fold selectivity. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00022-x
• 作为产物：
  描述：

  2-(2-甲氧基乙氧基)乙酸 、 丙二酸单乙酯 在 magnesium ethylate 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 为溶剂， 反应 53.5h， 生成 4-(2-methoxy-ethoxy)-3-oxo-butyric acid ethyl ester
  参考文献：
  名称：

  [EN] 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS
  [FR] DÉRIVÉS 5-[(PIPÉRAZINE-1-YL) -3-OXO-PROPYL]-IMIDAZOLIDINE -2,4-DIONE COMME INHIBITEURS D'ADAMTS POUR LE TRAITEMENT DE L'ARTHROSE

  摘要：

  本发明公开了根据式(I)的化合物，其中R、R2、R3a、R3b和Cy如本文所定义。本发明公开了抑制ADAMTS的化合物、其制备方法、包含该化合物的药物组合物以及用于预防和/或治疗涉及软骨降解和/或软骨稳态破坏的炎症状况和/或疾病的方法。

  公开号：

  WO2016102347A1

文献信息

• Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridine
  作者：David Alker、Simon F. Campbell、Peter E. Cross

  DOI：10.1021/jm00105a004

  日期：1991.1

  4-dihydropyridine (2) is described, and its potent calcium antagonist activity on rat aorta (IC50 = 4 x 10(-9) M) and marked tissue selectivity in vitro for vascular smooth muscle over cardiac smooth muscle are established. In order to exploit the excellent in vitro profile of compound 2, a range of analogues were prepared but none were found to have superior calcium antagonist potency and tissue selectivity. Compound

  描述了4-（2,3-二氯苯基）-3-（乙氧基羰基）-2-[（2-羟基乙氧基）甲基] -5-（甲氧基羰基）-6-甲基-1,4-二氢吡啶的制备（2） ，并建立了其对大鼠主动脉的强钙拮抗剂活性（IC50 = 4 x 10（-9）M）和体外对血管平滑肌优于心脏平滑肌的明显组织选择性。为了利用化合物2的出色的体外特性，制备了一系列类似物，但没有一个具有出色的钙拮抗剂效价和组织选择性。化合物2在麻醉的狗中具有出色的体内活性（ED50 = 12微克/ kg，可降低CVR），在清醒的狗中血浆半衰期为7.2小时。将2的药代动力学参数与对结构相关化合物氨氯地平和非洛地平测定的参数进行比较。
• [EN] PROCESS FOR THE PRODUCTION OF SUBSTITUTED NICOTINIC ACID ESTERS<br/>[FR] PROCEDE DE PRODUCTION D'ESTERS D'ACIDES NICOTINIQUES SUBSTITUES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2004078729A1

  公开（公告）日：2004-09-16

  The present invention relates to a process for the preparation of compounds of formula (I) wherein the substituents are as defined in claim 1, by reaction of a compound of formula (II) wherein R3 is C1-C8alkyl or C3-C6cycloalkyl and R4 and R05 are as defined for formula (I), with a compound of formula (III) wherein R, R1, R2 and X1, are as defined for formula (I) in claim 1, in an inert solvent in the presence of a proton source.

  本发明涉及一种制备式(I)化合物的过程，其中取代基如权利要求1所定义，通过将式(II)化合物（其中R3为C1-C8烷基或C3-C6环烷基，R4和R05如式(I)所定义）与式(III)化合物（其中R、R1、R2和X1如权利要求1所定义）在惰性溶剂中，在质子源存在下反应。
• HETEROCYCLIC AZA COMPOUNDS
  申请人：Grünenthal GmbH

  公开号：EP3130589A1

  公开（公告）日：2017-02-15

  The invention relates to heterocyclic aza compounds as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

  本发明涉及杂环氮化物作为vanilloid受体配体，含有这些化合物的制药组合物，以及这些化合物用于治疗和/或预防疼痛和其他疾病和/或障碍的用途。
• Method for preparation of 6-trifluoromethylpyridine-3-carboxylic acid derivatives from 4,4,4-trifluoro-3-oxobutanoyl chloride
  申请人：Lonza Ltd

  公开号：EP2821399A1

  公开（公告）日：2015-01-07

  The invention discloses a method for the preparation of substituted 6-trifluoromethylpyridine-3-carboxylic acid derivatives starting from 4,4,4-trifluoro-3-oxobutanoyl chloride via respective intermediates and respective steps.

  本发明公开了一种从4,4,4-三氟-3-氧代丁酰氯出发，通过各自的中间体和各自的步骤制备取代的6-三氟甲基吡啶-3-羧酸衍生物的方法。
• Pyrrol derivatives with antibacterial activity
  申请人：Green Morenike Oluyinka

  公开号：US20060223801A1

  公开（公告）日：2006-10-05

  Compounds of Formula (1) and their pharmaceutically acceptable salts are described: Formula (1) Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  本文描述了化学式（1）的化合物及其药用可接受的盐：化学式（1）。同时描述了其制备方法、含有它们的药物组合物、作为药物的用途以及在治疗细菌感染方面的应用。